Revvity (NYSE:RVTY) Announces Earnings Results, Beats Expectations By $0.20 EPS

Revvity (NYSE:RVTY) released its earnings results on Tuesday. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20, Zacks reports. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 earnings per share. Revvity updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity reported Q2 revenue of $711 million, 3% pro forma organic growth, and adjusted EPS of $1.41, exceeding expectations. Performance benefited from stronger operations, favorable tax timing, and $16 million in tariff refunds.
• The company raised its 2026 outlook to 4%–5% organic growth, approximately 28.7% adjusted operating margin, and adjusted EPS of $5.30–$5.40. Management said the guidance assumes continued improvement in pharma and biotech spending but no further acceleration beyond current trends.
• Diagnostics remained a major strength, growing 11% organically, with reproductive health up in the mid-teens and Immunodiagnostics outside China accelerating to high-single-digit growth. Newborn screening and the Genomics England sequencing contract continued to support results.
• AI-related demand is driving increased orders for high-content screening instruments, particularly the Opera Phenix OptIQ, with double-digit growth and backlog exceeding near-term production capacity. Management expects subsequent reagent pull-through as customers expand their lab-in-the-loop workflows.
• Signals software revenue declined approximately 20% year over year because of contract timing and difficult comparisons, although annualized portfolio value and ARR continued to grow strongly. Management expects a return to double-digit organic growth in the second half, making the recovery dependent on renewals and adoption of new AI-enabled offerings.

Revvity Trading Up 2.4%

RVTY opened at $115.21 on Tuesday. The business has a 50 day simple moving average of $106.88 and a two-hundred day simple moving average of $99.92. The firm has a market capitalization of $12.85 billion, a price-to-earnings ratio of 55.12, a PEG ratio of 2.21 and a beta of 1.07. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41. Revvity has a one year low of $81.22 and a one year high of $118.30.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s payout ratio is currently 13.40%.

Hedge Funds Weigh In On Revvity

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in Revvity by 5.2% in the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock worth $883,000 after acquiring an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Revvity by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock valued at $1,246,000 after acquiring an additional 744 shares in the last quarter. Millennium Management LLC increased its position in Revvity by 102.0% during the 1st quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock valued at $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. raised its holdings in Revvity by 45.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after purchasing an additional 189,871 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in Revvity by 13.0% in the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after purchasing an additional 811 shares in the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on RVTY. Robert W. Baird set a $117.00 price target on shares of Revvity in a research note on Wednesday, May 6th. Evercore reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a research note on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. The Goldman Sachs Group decreased their target price on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 14th. Finally, Zacks Research lowered shares of Revvity from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Revvity has an average rating of “Hold” and a consensus price target of $108.36.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.